ArticleParkinson's disease2012
Gene therapy for Parkinson's disease.
Article in Parkinson's disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Unravelling the Role of Tyrosine and Tyrosine Hydroxylase in Parkinson's Disease: Exploring Nanoparticle-based Gene Therapies.CNS & neurological disorders drug targets · 2025Review
- Myokines and Resistance Training: A Narrative Review.International journal of molecular sciences · 2022Review
- cAMP Response Element Binding-Protein- and Phosphorylation-Dependent Regulation of Tyrosine Hydroxylase by PAK4: Implications for Dopamine Replacement Therapy.Molecules and cells · 2021Article
- BDNF as a Promising Therapeutic Agent in Parkinson's Disease.International journal of molecular sciences · 2020Review
- Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis.Neurochemical research · 2016Review
- Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.Journal of neurophysiology · 2016Review
- Regenerative medicine for Parkinson's disease.Neurologia medico-chirurgica · 2015Review
- Parkinson's disease gene therapy: success by design meets failure by efficacy.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Review
- Transfection of the glial cell line-derived neurotrophic factor gene promotes neuronal differentiation.Neural regeneration research · 2014Article
- Targeted delivery of nano-therapeutics for major disorders of the central nervous system.Pharmaceutical research · 2013Review
- Gene therapy for misfolding protein diseases of the central nervous system.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current pharmacological and surgical treatments for Parkinson's disease offer symptomatic improvements to those suffering from this incurable degenerative neurological disorder, but none of these has convincingly shown effects on disease progression. Novel approaches based on gene therapy have several potential advantages over conventional treatment modalities. These could be used to provide more consistent dopamine supplementation, potentially providing superior symptomatic relief with fewer side effects. More radically, gene therapy could be used to correct the imbalances in basal ganglia circuitry associated with the symptoms of Parkinson's disease, or to preserve or restore dopaminergic neurons lost during the disease process itself. The latter neuroprotective approach is the most exciting, as it could theoretically be disease modifying rather than simply symptom alleviating. Gene therapy agents using these approaches are currently making the transition from the laboratory to the bedside. This paper summarises the theoretical approaches to gene therapy for Parkinson's disease and the findings of clinical trials in this rapidly changing field.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.